The UAE Is Leaving OPEC, Oil Is at $111, and OpenAI Missed Its Own Revenue Targets

The WSJ reported Tuesday that OpenAI has missed its own internal revenue and user growth targets, with the CFO raising concerns about the company’s ability to pay for future computing contracts. Chip stocks fell immediately as investors questioned whether the AI infrastructure spending boom is running ahead of actual AI revenue.

Today’s write-up has every name that moved and what it means heading into tomorrow’s Magnificent Seven earnings.

Talk of a major financial executive order is putting renewed focus on U.S. monetary policy.

Some analysts believe a shift like this could impact everything from savings to asset prices—including gold.

The last time a major policy change occurred, certain assets saw significant long-term moves.

Now, investors are watching closely for what may come next.

See what this could mean for gold

A CEO sold a combined $11.2 million worth of stock across three straight sessions. On the flip side, a healthcare giant saw a $2.7 million proposed sale and a fresh $201,300 buy from its CFO. The full breakdown is inside today’s Insider section.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money-back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Chip stocks dropped sharply after the WSJ reported that OpenAI missed its own internal revenue and user growth targets, sending Oracle down 4%, Broadcom down 4%, and Nvidia down 1% as investors reconsidered whether AI infrastructure spending is running ahead of actual AI revenue generation.

Oil crossed $111 per barrel as the Strait of Hormuz remained closed, gas prices hit $4.18 per gallon at the national average, the highest since August 2022, and the UAE announced it will exit OPEC on May 1, removing the third-largest producer from the cartel.

Earnings were mixed: Coca-Cola and General Motors beat, Centene and Kforce surged, while Spotify fell on weak guidance. All ahead of a critical slate from Alphabet, Amazon, Meta, and Microsoft.

BlackRock Inc's (NYSE: BLK) tokenized U.S. Treasury fund BUIDL is now accepted as trading collateral on a major crypto exchange. Institutional clients can use their BUIDL holdings to back trades without moving assets between custodians and exchanges.

BlackRock launched BUIDL as a tokenized fund. It is now functioning as infrastructure.

From Fund to Financial Primitive

Most funds just hold assets and pay returns. BUIDL is doing something different. It is becoming a building block that other financial services plug into. Using it as collateral means institutional traders treat it the same way they treat cash or Treasury bills in traditional finance.

That evolution matters. You launch a fund, and it stays a fund forever. BlackRock launched a fund and turned it into a tool that rewires how institutional trading works.

Tokenization Gets Real

BlackRock has talked about tokenization for years. BUIDL is where that vision becomes tangible. The fund invests in cash, Treasury bills, and repurchase agreements. It distributes yield on-chain. And now it functions as collateral inside a live trading environment.

BlackRock manages over $10 trillion. It runs the largest bitcoin ETF. It operates the largest tokenized fund. And now that fund is embedded inside crypto trading infrastructure backed by a globally significant bank.

You connect those dots, and BlackRock is not just participating in crypto. It is building the institutional layer that everything else runs on.

Gilead Sciences (NASDAQ: GILD) just completed its $7.8 billion acquisition of Arcellx, a cell therapy company developing next-generation treatments for blood cancers. The deal is done. Arcellx is now fully inside Gilead. And Gilead's oncology ambitions just jumped to an entirely different level.

Cell Therapy Is the Future of Cancer Treatment

Traditional cancer drugs broadly attack the disease. Cell therapy reprograms a patient's own immune system to hunt and destroy cancer cells with precision. Arcellx developed a differentiated approach that addresses limitations in current cell therapies, making treatment more effective for patients who have exhausted their options.

Gilead already owns Kite, its existing cell therapy division. Adding Arcellx gives it a second, more advanced platform. You do not spend $7.8 billion to duplicate what you already have. Gilead is building a cell therapy portfolio with depth that no single competitor can match.

HIV Funded This Moment

Gilead generates massive, predictable cash flow from its HIV franchise. That revenue stream has been funding the company's oncology expansion for years. Arcellx is the biggest single investment yet in that transformation.

The playbook is clear. Harvest profits from a dominant existing business and reinvest them into the next frontier of medicine. Your understanding of Gilead must account for the fact that it is no longer primarily an HIV company. It is becoming an oncology powerhouse funded by HIV.

No one believed Whitney Tilson when he predicted the collapse of Bear Stearns and Lehman Brothers. Or when he went on 60 Minutes exposing a company poisoning its own customers. (The stock fell nearly 80%.)

Now he has a new warning about what's REALLY around the corner for America's most beloved tech companies.

Watch for free here.

FedEx (NYSE: FDX) just made it clear that it is not waiting for demand to bounce back. The company is aggressively reshaping its operations through a major internal program designed to cut costs, streamline its network, and adapt to a slower shipping environment.

The backdrop matters here. Global shipping demand has softened, and FedEx is responding by taking control of what it can, which is its own cost structure and efficiency.

A Leaner FedEx Is Emerging

FedEx is reducing flights, parking aircraft, and adjusting its workforce to match current demand better. These are big operational decisions that change how the company functions day to day. You are looking at a company that is actively resizing itself instead of waiting for conditions to improve.

This approach is about staying ahead of the cycle. It allows FedEx to protect its business even when volumes are not growing as expected.

Efficiency Is Becoming the Strategy

The company is focusing heavily on doing more with less. By improving how its network operates, FedEx aims to move packages faster and more cheaply. That shift is becoming central to how it competes going forward.

Your takeaway should be that FedEx is not just reacting to weak demand; it is redesigning its entire system to be more efficient long term.

Momentum is building around efficiency and profitability. You could see FedEx come out stronger on the other side of this transition, because companies that adapt early tend to lead when conditions improve again.

Kforce [KFRC] $44.93 (+41.36%)

Kforce reported Q1 EPS of $0.46, beating the $0.39 consensus, with revenue of $330.4 million representing the company’s first year-over-year revenue increase in several years. Q2 guidance calls for 4% YoY revenue growth and EPS at the midpoint, implying a 20% year-over-year increase.

The data and AI talent pipeline grew 50% year-over-year, confirming the staffing recovery is real and concentrated in the highest-demand verticals.

Edesa Biotech [EDSA] $13.80 (+27.93%)

Edesa reported additional positive Phase 3 results for paridiprubart in ARDS patients in February and continues running on the sustained biotech sector tailwind that has been pulling capital into clinical-stage names all month.

At a $122 million Strong Buy market cap with 3.23x relative volume, the move reflects institutional interest in a pipeline that includes both respiratory and dermatology programs with active Phase 3 data momentum.

Kiniksa Pharmaceuticals [KNSA] $54.00 (+23.82%)

Kiniksa reported Q1 ARCALYST revenue of $214.3 million, up 56% year-over-year, and raised its full-year guidance to $930-945 million from $900-920 million. Net income came in at $22.6 million on $468.1 million in cash with zero debt.

ARCALYST treats recurrent pericarditis and is growing prescriber base in both new and repeat categories, confirming the revenue trajectory is durable rather than one-time.

High-Trend International [HTCO] $8.10 (-78.81%)

HTCO’s Monday 327% surge on the lithium transportation pivot fully reversed Tuesday as momentum sellers overwhelmed the thin float. The company has 18 employees, no analyst coverage, and negative EBITDA, making yesterday’s move pure momentum rather than fundamental repricing.

At 1.87x average volume, the selling is orderly rather than panicked, which confirms this is profit-taking from Monday’s buyers rather than a new negative catalyst.

Erasca [ERAS] $9.83 (-48.67%)

Erasca reported positive Phase 1 data for ERAS-0015 on April 27, including 75% unconfirmed response rates in KRAS G12X lung cancer and 50% in second-line pancreatic cancer at the 32mg dose. But simultaneously disclosed a letter from Revolution Medicines alleging ERAS-0015 infringes Revolution’s patents and involves misappropriated trade secrets.

The patent dispute against the lead asset overwhelmed the positive clinical data and triggered a catastrophic selloff on volume at 5x average.

Rambus [RMBS] $111.77 (-20.90%)

Rambus reported Q1 EPS of $0.63 versus the $0.64 consensus, a one-cent miss, on revenue of $180.2 million that beat estimates.

The market responded by selling the stock 20% because Rambus licenses memory interface IP to chip makers, and the OpenAI revenue miss report raised immediate questions about whether AI chip demand is as robust as its $12 billion valuation and 52x P/E ratio requires.

His official salary? $400,000 a year.

But his tax returns reveal something unexpected: Up to $250,000 per month from a single source.

It’s not real estate.
It’s not stocks.

So what is it — and why are more investors paying attention now?

Discover how you could get started for under $20

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.